share_log

Reported Late Wednesday, HUTCHMED's Tazemetostat For Relapsed/Refractory Follicular Lymphoma Secures NDA Acceptance And Priority Review In China

Reported Late Wednesday, HUTCHMED's Tazemetostat For Relapsed/Refractory Follicular Lymphoma Secures NDA Acceptance And Priority Review In China

据周三晚报导,福修康美药业的Tazemetostat用于复发/难治性滤泡性淋巴瘤已获中国新药申请受理并获得优先审评。
Benzinga ·  07/05 03:02

Reported Late Wednesday, HUTCHMED's Tazemetostat For Relapsed/Refractory Follicular Lymphoma Secures NDA Acceptance And Priority Review In China

据周三晚报导,福修康美药业的Tazemetostat用于复发/难治性滤泡性淋巴瘤已获中国新药申请受理并获得优先审评。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发